Lastly, findings in HNSCC-PDX, PDC, and engineered cell models showed that RAC1-amplification and A159V hotspot mutation, but not P29S, are, in principle, druggable with preclinical Rac targeting. This evidence concerns the gene RAC1 and head and neck squamous cell carcinoma.